Platelet Aggregation, Spontaneous

In this study, researchers want to learn if 2 different forms of acetylsalicylic acid (ASA) chewable tablets will have the same effect in the body. For this, they compared the blood levels of a new form of ASA chewable tablet, which is manufactured at a different site, with an approved ASA chewable tablet, on an empty stomach in healthy participants. This is done as part of the regulatory requirement for the marketing approval of the new ASA chewable tablet.
The study treatment, ASA, is an antiplatelet drug. It works by making the blood thinner and stopping the blood from clotting.
In this study, participants will be healthy and will not benefit from taking ASA chewable tablets. However, the study will provide information on how the new ASA chewable tablet, which is manufactured at a different site, has an effect on the body.
The main purpose of this study is to compare blood levels of the new ASA chewable tablet with the approved ASA chewable tablet when taken as a single dose on an empty stomach.
For this, the researchers will analyze:
* Area under the curve (AUC): a measure of the total amount of ASA in participants' blood over time
* Maximum observed concentration (Cmax): the highest amount of ASA in participants' blood after a single dose without food
This study will have 3 treatment periods of 4 days each. In each period, participants will take either the new or approved ASA chewable tablet on an empty stomach according to the order assigned to them. The 2 treatment sequences in this study are:
New chewable tablet, approved chewable tablet, new chewable tablet
Approved chewable tablet, new chewable tablet, approved chewable tablet
Each participant will be in the study for around 7 weeks, which includes:
* a visit within 21 days of the first period to confirm if the participant can take part in the study
* hospital stay of around 2 days in each period, during which, participants will take their assigned treatment, and have blood tests to check for drug levels
* a gap of 1 week after taking the treatment in each period
During the study, the doctors and their study team will:
* measure the level of the study treatment by taking blood samples
* check participants' health by performing urine tests, checking vital signs and checking heart health using an electrocardiogram (ECG)
* ask the participants questions about how they are feeling and what adverse events they are having
An adverse event is any medical problem that a participant has during a study. The study doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
As this study is conducted in healthy participants who will not benefit from the treatment, access to the treatment after the study is not planned.

International multicenter, investigator-driven, open-label, randomized (1:1) clinical trial to observe and evaluate the rate of ischemic and bleeding adverse events of a single antiplatelet regimen (SAPT) since the time of PCI with latest generation DCB in elderly or HBR population with stable or unstable coronary syndromes.

The objectives of this clinical trial are to 1) determine the effect of the TP compared to placebo on blood flow and platelet aggregation, 2) to determine the effect of the TP on cardiovascular health compared to a placebo and 3) to assess the safety and tolerability of the TP in healthy adults.